Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2008 Oct;30(5):591-6.
doi: 10.1097/FTD.0b013e3181858169.

Impact of changing from cyclosporine to tacrolimus on pharmacokinetics of mycophenolic acid in renal transplant recipients with diabetes

Jeong M Park  1 , Kathleen D Lake, Diane M Cibrik
Affiliations
Comparative Study

Impact of changing from cyclosporine to tacrolimus on pharmacokinetics of mycophenolic acid in renal transplant recipients with diabetes

Jeong M Park et al. Ther Drug Monit. 2008 Oct.

Abstract

The rate of mycophenolic acid (MPA) absorption after oral administration of mycophenolate mofetil (MMF) is delayed in patients with diabetes. Cyclosporine (CsA) decreases MPA exposure by inhibiting enterohepatic recirculation of MPA/MPA glucuronide, and tacrolimus (TRL) may alter the rate and extent of MPA absorption due to its prokinetic properties especially in patients with diabetic gastroparesis. This study evaluated the effect of changing from CsA to TRL on pharmacokinetics of MPA in stable renal transplant recipients with long-standing diabetes. Eight patients were switched from a stable dose of CsA to TRL while taking MMF 1 g twice daily. The 12-hour steady-state total plasma concentration-time profiles of MPA and MPA glucuronide were obtained after oral administration of MMF on 2 occasions: first while taking CsA and second after changing to TRL. Pharmacokinetic parameters of MPA were calculated by the noncompartmental method. Changing from CsA to TRL resulted in significantly increased MPA exposure (area under the concentration-time curve from 0 to 12 hours, AUC0-12) by 46 +/- 32% (P = 0.012) and MPA predose concentration (C0) by 121 +/- 67% (P = 0.008). The magnitude of change in MPA exposure did not correlate well with MPA-C0 or CsA trough concentration. Switching to TRL had minimal impact on peak concentration of MPA (15.0 +/- 6.9 mg/L with CsA versus 16.1 +/- 9.7 mg/L with TRL, P = 0.773) and time to reach the peak concentration (1.0 +/- 0.4 hours with CsA versus 1.2 +/- 0.8 hours with TRL, P = 0.461). Highly variable and unpredictable changes in MPA exposure among renal transplant patients with diabetes do not support a strategy of preemptively adjusting MMF dose when switching calcineurin inhibitors in this population.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Mean plasma concentration–time profile for (A) mycophenolic acid (MPA) and (B) mycophenolic acid glucuronide (MPAG) after oral administration of MMF with CsA (open circle) and TRL (closed circle). Error bars represent SD of the mean (n = 8).
FIGURE 1
FIGURE 1
Mean plasma concentration–time profile for (A) mycophenolic acid (MPA) and (B) mycophenolic acid glucuronide (MPAG) after oral administration of MMF with CsA (open circle) and TRL (closed circle). Error bars represent SD of the mean (n = 8).
FIGURE 2
FIGURE 2
Changes in (A) AUC0–12 and (B) predose plasma concentration (C0) of mycophenolic acid (MPA) after change of concomitant CNI from CsA to TRL (thin line: individual subject; thick line: mean; n = 8).
FIGURE 2
FIGURE 2
Changes in (A) AUC0–12 and (B) predose plasma concentration (C0) of mycophenolic acid (MPA) after change of concomitant CNI from CsA to TRL (thin line: individual subject; thick line: mean; n = 8).
See this image and copyright information in PMC

References

    1. Zucker K, Rosen A, Tsaroucha A, et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patient receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transplant Immunol. 1997;5:225–232. - PubMed
    1. Hübner GI, Eismann R, Sziegoleit W. Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients. Ther Drug Monit. 1999;21:536–539. - PubMed
    1. Smak Gregoor PJH, de Sévaux RGL, Hené RJ, et al. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation. 1999;68:1603–1606. - PubMed
    1. Pou L, Brunet M, Cantarell C, et al. Mycophenolic acid plasma concentrations: influence of comedication. Ther Drug Monit. 2001;23:35–38. - PubMed
    1. Shipkova M, Armstrong VW, Kuypers D, et al. Effect of cyclosporine withdrawal on mycophenolic acid pharmacokinetics in kidney transplant recipients with deteriorating renal function: preliminary report. Ther Drug Monit. 2001;23:717–721. - PubMed

Publication types